Novartis Cosentyx® gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis

  • Cosentyx® (secukinumab) is the first biologic with proven efficacy in all 6 key manifestations of psoriatic arthritis (PsA), and the only biologic with fast and lasting relief of axial manifestations of PsA in a dedicated trial1,2,3.
  • Up to two-thirds of patients with PsA suffer from axial manifestations4
  • Phase IIIb MAXIMISE trial showed treatment with Cosentyx improved the signs and symptoms of axial manifestations of PsA as early as …
/by

Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease

  • Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation 
  • Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies
  • Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa …
/by

Novartis Entresto® granted expanded indication in chronic heart failure by FDA

  • Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF)1-3 
  • Expanded indication enables potential treatment of more adults with left ventricular ejection fraction (LVEF) below normal, the group where benefits are most clearly evident1 
  • Of the more than 6 million Americans …
/by

Novartis data show multiple sclerosis patients and nurses prefer Kesimpta® (ofatumumab) Sensoready® autoinjector pen

  • Multicenter survey results show MS patients and nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta over other autoinjectors for their current treatment (84% vs 16%)1 
  • Sensoready autoinjector pen ranked highest for “easy to perform self-injection with the pen,” “patient able to use independently” and “ease of preparation and set-up” by both patients and nurses1 
  • Kesimpta is a targeted B-cell therapy that delivers superior efficacy and post hoc analysis showed that …
/by

Expanding CAR-T manufacturing in Australia

Basel, February 12, 2021 – Novartis today announced it has received approval from the Therapeutic Goods Administration (TGA) for Cell Therapies to manufacture and supply its CAR-T therapies commercially for eligible patients in Australia. The Cell Therapies manufacturing facility in the Peter MacCallum Cancer Center in Melbourne is the first and only approved commercial manufacturing site for CAR-T cell therapies in Australia.

As a pioneer in individualized medicine, Novartis is committed to reimagining cancer care in the emerging field of …

/by

Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics

  • Sandoz to acquire three established brands sold in more than 100 markets
  • Acquisition, including leading global brand Zinnat®, confirms Sandoz commitment to antibiotics, following plans to expand its integrated manufacturing site in Kundl
  • Transaction complements Sandoz leadership in generic penicillins with a leading position in cephalosporins – largest antibiotic segment by global sales

Basel, February 11, 2021 – Sandoz, a Novartis division, has signed an agreement to acquire …

/by
Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics
  • Sandoz to acquire three established brands sold in more than 100 markets
  • Acquisition, including leading global brand Zinnat®, confirms Sandoz commitment to antibiotics, following plans to expand its integrated manufacturing site in Kundl
  • Transaction complements Sandoz leadership in generic penicillins with a leading position in cephalosporins – largest antibiotic segment by global sales

Basel, February 11, 2021 – Sandoz, a Novartis division, has signed an agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading …

/by

Novartis receives FDA Breakthrough Therapy designations for investigational STAMP inhibitor asciminib (ABL001) in chronic myeloid leukemia

  • Designation in patients with chronic myeloid leukemia (CML) resistant or intolerant to prior treatments based on positive data from pivotal Phase III ASCEMBL trial evaluating asciminib, an investigational treatment specifically targeting the ABL myristoyl pocket (STAMP)1,2 
  • Despite advances in CML care, many patients are at risk of disease progression, and sequential TKI therapy may be associated with increased resistance and intolerance3-9 
  • Breakthrough …
/by

World Cancer Day 2021

The series explores cancer, cures and everything in between through the perspectives of our own President of Oncology, Dr. Susanne Schaffert, as well as industry experts Dr. Paul Farmer, Dr. Michel Coleman, and cancer campaigner, Deborah James.

Each month, we’ll release new content focused on important topics like access, survivorship and precision medicine. Stay tuned for more!

An Introduction

In this documentary, which kicks off the series, Dr. Susanne Schaffert speaks with …

/by

Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis

  •  Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1

  • CHMP opinion is based on two Phase III ASCLEPIOS studies that met the primary endpoints where Kesimpta showed a reduction of the annual relapses by over 50% versus teriflunomide and achieved more than 30% relative risk reduction of 3-month confirmed disability progression (CDP) 1

  • In a post hoc analysis, nearly …
/by